



**HAL**  
open science

## Characterization and in vitro evaluation of a vaginal gel containing *Lactobacillus crispatus* for the prevention of gonorrhoea

K C N'Guessan Gnaman, S. Bouttier, A. Yeo, A.A.S. a S Aka Any-Grah, S. Geiger, N. Huang, V. Nicolas, S. Villebrun, H. Faye-Kette, G. Ponchel, et al.

### ► To cite this version:

K C N'Guessan Gnaman, S. Bouttier, A. Yeo, A.A.S. a S Aka Any-Grah, S. Geiger, et al.. Characterization and in vitro evaluation of a vaginal gel containing *Lactobacillus crispatus* for the prevention of gonorrhoea. *International Journal of Pharmaceutics*, 2020, 588, pp.119733. 10.1016/j.ijpharm.2020.119733 . hal-03342902

**HAL Id: hal-03342902**

**<https://hal.inrae.fr/hal-03342902>**

Submitted on 13 Sep 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright



## Characterization and *in vitro* evaluation of a vaginal gel containing *Lactobacillus crispatus* for the prevention of gonorrhoea

K.C. N'Guessan Gnaman<sup>a,b</sup>, S. Bouttier<sup>c,1</sup>, A. Yeo<sup>d,1</sup>, A.A.S. Aka Any-Grah<sup>b,1</sup>, S. Geiger<sup>a,1</sup>, N. Huang<sup>a</sup>, V. Nicolas<sup>e</sup>, S. Villebrun<sup>a</sup>, H. Faye-Kette<sup>d</sup>, G. Ponchel<sup>a</sup>, A.A. Koffi<sup>b,2</sup>, F. Agnely<sup>a,2,\*</sup>

<sup>a</sup> Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 92290 Châtenay-Malabry, France

<sup>b</sup> Laboratoire de Pharmacie Galénique, Cosmétologie et Législation Pharmaceutique, UFR des Sciences Pharmaceutiques et Biologiques d'Abidjan, Université Félix Houphouët-Boigny, 01 BP V 34 Abidjan 01, Côte d'Ivoire

<sup>c</sup> INRAE, AgroParisTech, Micalis Institute, Équipe Bactéries pathogènes et santé, Université Paris-Saclay, 92290 Châtenay-Malabry, France

<sup>d</sup> Institut Pasteur, Département de microbiologie, Unité des agents du tractus génital, Abidjan, Côte d'Ivoire

<sup>e</sup> Université Paris-Saclay, SFR-UMS-IPSIT, Plateforme d'imagerie cellulaire MIPSIT, 92290 Châtenay-Malabry, France

### ARTICLE INFO

#### Keywords:

Confocal laser scanning microscopy

Gel

Gonorrhoea prevention

*Lactobacillus*

Probiotics

Rheology

Vaginal administration

### ABSTRACT

The increasing resistance of *Neisseria gonorrhoeae* to any current antibiotic treatment and the difficulties associated with the use of prevention means such as condom urge the need for alternative methods to prevent this sexually transmitted infection. In this work, a prevention strategy based on the use of a vaginal gel containing *Lactobacilli* was assessed *in vitro*. A *Lactobacillus crispatus* strain (ATCC 33197) was selected based on the published data on its ability to inhibit *Neisseria gonorrhoeae*. Its probiotic properties were first characterized. Then, a thermo-sensitive hydrogel containing 21.5% of poloxamer 407, 1% of sodium alginate and 9 log<sub>10</sub> CFU of *Lactobacillus crispatus* per gel sample (5 g) was developed. The gelation temperature and the rheological characteristics of this formulation appeared suitable for a vaginal administration. *Lactobacillus crispatus* was viable in the gel for six months although a large amount of the bacteria was not culturable. The ability of *Lactobacillus crispatus* to inhibit *Neisseria gonorrhoeae* was still observed with the gel. Such system, thus, appeared promising for the prevention of gonorrhoea.

### 1. Introduction

Gonorrhoea is a sexually transmitted infection that is caused by *Neisseria gonorrhoeae*. With 78 million new cases every year (WHO, 2016), it has become a major public health issue for many reasons. Indeed, this infection remains more often asymptomatic in women, which favors its spreading. It can induce severe damages such as infertility both in men and women, and blindness in newborns (Grodstein et al., 1993; Laga et al., 1986). It also increases the risk of contracting human immunodeficiency virus HIV (Cohen, 2004; Jarvis and Chang, 2012). Resistance to several antibiotics even to the last intention treatments is currently emerging (Lefebvre et al., 2018). Some untreatable strains that are insensitive to any known antimicrobial

treatment are now circulating. Meanwhile, neither vaccines nor new drugs are emerging on the market. Condom which is the sole effective prevention mean is unfortunately either not well or insufficiently used. Thus, gonorrhoea has become difficult to treat or to prevent. The main target of gonorrhoea, as all sexually transmitted infections, is women because they are more vulnerable. A strategy giving women the control of their own protection could enable to achieve better results in the field of prevention (Stein, 1990). Thus, recent studies are devoted to woman-controlled means intended for a vaginal administration (Minnis and Padian, 2005; Traore et al., 2018).

Promising approaches based on probiotics have been developed for the prevention of women urogenital tract infections (Bruce and Reid, 1988; Stapleton et al., 2011). Probiotics are defined as “live

**Abbreviations:** A, sodium alginate; ATCC, american type culture collection; BHIA, brain heart infusion agar; CDC, Center for disease control; CFU, colony forming unit; CLSM, confocal laser scanning microscopy; G', elastic modulus; G'', viscous modulus; GC agar, chocolate agar; HIV, human immunodeficiency virus; *L. crispatus*, *Lactobacillus crispatus*; MRS, Man-Rogosa-Sharpe; *N. gonorrhoeae*, *Neisseria gonorrhoeae*; P, Poloxamer 407; PBS, phosphate buffered saline; pH<sub>i</sub>, initial pH; SVF, simulated vaginal fluid; T<sub>gel</sub>, gelation temperature; VNC, viable but nonculturable

\* Corresponding author.

E-mail address: [florence.agnely@universite-paris-saclay.fr](mailto:florence.agnely@universite-paris-saclay.fr) (F. Agnely).

<sup>1</sup> These authors have contributed equally.

<sup>2</sup> These authors have contributed equally.

<https://doi.org/10.1016/j.ijpharm.2020.119733>

Received 29 April 2020; Received in revised form 31 July 2020; Accepted 1 August 2020

Available online 05 August 2020

0378-5173/ © 2020 Elsevier B.V. All rights reserved.

microorganisms that, when administered in adequate amounts, confer a health benefit on the host" (Hill et al., 2014). The most important probiotic *genus* studied for urogenital infections is *Lactobacillus*. The healthy vaginal flora is typically dominated by *Lactobacillus* (*L.*) species, such as *L. iners*, *L. crispatus*, *L. jensenii* and *L. gasseri* (Pavlova et al., 2002; Ravel et al., 2011), but *L. crispatus* seems to largely prevail over the other *Lactobacillus* strains (Antonio et al., 1999; Vasquez et al., 2002). Moreover, *L. crispatus* has been reported to promote the stability of the normal vaginal flora (Verstraelen et al., 2009). Vaginal colonization with a human *L. crispatus* strain had been successful (Antonio and Hillier, 2003). A *L. crispatus* strain was also used successfully as a vaginal suppository for healthy women with a history of recurrent urinary tract infections (Czaja et al., 2007; Stapleton et al., 2011) and for the treatment of bacterial vaginosis (Hemmerling et al., 2010). Moreover, it was shown that *L. crispatus* inhibited the infectivity of *N. gonorrhoeae* *in vitro* (Amant et al., 2002) and *ex vivo* (Breshears et al., 2015). Its use for a vaginal administration could be a valuable strategy for vaginal gonorrhea prevention. Therefore, *L. crispatus* was selected in the present study. As the health promoting effects of probiotics are usually strain specific, we report, in this work, on the ability of a reference vaginal *L. crispatus* strain ATCC 33197 to be used as a probiotic for the prevention of gonorrhea.

The vaginal route has been selected instead of the oral route to obtain a maximal local effect while avoiding interferences with the gastrointestinal tract. Different strains of *L. crispatus* are already administered as capsules, vaginal suppositories or tablets (Nader-Macias and Juarez Tomas, 2015). However, these conventional dosage forms are associated to an inhomogeneous repartition in the vagina (Palmeira-de-Oliveira et al., 2015). In this study, we focused on the design of a gel form intended for the administration of this *L. crispatus* strain. Hydrogels are already used and well accepted for vaginal administration. They can easily spread over the vaginal mucosa, they are easy to be prepared and have a low cost of production (Cook and Brown, 2018; Pilcher, 2004). Besides, they can be self-administered without partner knowledge. Several studies have been focused on the formulation of viscoelastic and temperature-sensitive hydrogels based on poloxamer 407, with remanence capacity at the vaginal mucosa and sufficient resistance to dilution in presence of vaginal fluids (Aka-Any-Grah et al., 2010; Huang et al., 2016; Liu et al., 2009). In aqueous solution, this synthetic poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer forms micelles above a critical micelle concentration or temperature. If the polymer concentration is high enough and above a critical temperature called gelation temperature ( $T_{gel}$ ), these micelles organize themselves into a cubic liquid crystalline structure forming a gel (Dumortier et al., 2006). Poloxamer 407 can be mixed with mucoadhesive polymers such as cellulosic derivatives, polyacrylates or polysaccharides to reinforce remanence at the mucosal surface (Caramella et al., 2015; Rençber et al., 2017; Giuliano et al., 2018; Vigani et al., 2019). A clinical study conducted on 104 women investigated the vaginal administration of thermosensitive gels (poloxamer 407, 17% w/w, or poloxamer 407, 15% w/w, combined with hydroxyethyl cellulose, 1% w/w) containing sildenafil citrate (Soliman et al., 2017). Neither gel leakage nor side effects were reported. Among mucoadhesive polymers, sodium alginate is particularly attractive. Indeed, it is a natural polymer derived from brown algae that is commonly and widely used for drug delivery, cell encapsulation and immobilization (including *Lactobacillus*), wound dressing and enzymes immobilization (Chaluvadi et al., 2012; Lee and Mooney, 2012; Lin et al., 2004; Szekalska et al., 2016; Tønnesen and Karlsen, 2002). Poloxamer 407 and alginate are compatible (Grassi et al., 2006). Their mixture can be liquid at low or room temperature to allow easy administration and spreading on the vaginal surface, and then can undergo gelation at body temperature (Lin et al., 2004). Moreover, good tolerance and biocompatibility are expected. Indeed, a recent study showed that sodium alginate in oil-poloxamer organogels intended for vaginal administration of voriconazole were non-cytotoxic towards

HeLa and Vero cell lines (Querobino et al., 2019). Huang et al. (2016) also reported an absence of cytotoxicity in mouse fibroblast (L929) cell line of thermosensitive composite hydrogels based on poloxamer 407 and alginate used in transarterial embolization therapy. To the best of our knowledge, there is only one published study reporting the use of a gel for the administration of *Lactobacilli* into the vagina (Vigani et al., 2019). These authors developed two mixtures based on poloxamer 407 and methylcellulose loaded with *Lactobacillus gasseri* for preventing candidosis recurrences and they studied the viability of the probiotic over 24 h.

In the present study, the mixture of poloxamer 407 and sodium alginate was assessed as a matrix for *L. crispatus* in order to obtain a temperature-sensitive vaginal gel with adequate mechanical properties and capable to inhibit *N. gonorrhoeae*. The probiotic properties of the selected *L. crispatus* strain were first assessed. In a second step, the influence of *L. crispatus* on the thermogelling and viscoelastic properties of the mixture of poloxamer 407 and alginate was investigated by rheology at 25 °C, *i.e.* in administration conditions, and at 37 °C after dilution by simulated vaginal fluid (SVF) to mimic *in vivo* conditions after administration. The efficacy of the gel on *N. gonorrhoeae* was evaluated *in vitro* as well as the viability of the *L. crispatus* in the gel over a six-month period.

## 2. Materials and methods

### 2.1. Materials

*L. crispatus*, a reference strain, isolated from human vagina with collection numbers CIP 103603 (ATCC 33197; NCTC 4505; NCIMB 4505), and a reference strain *N. gonorrhoeae* with collection number CIP 107031 (ATCC 49226; CCM 4500; CCUG 26213; CDC 10.001; CNCTC 5194; DSM 9189) were purchased from Institut Pasteur (Paris). The strains were stored at  $-80$  °C in cryovials with the appropriate broth supplemented with 20% (v/v) glycerol. *Streptococcus pneumoniae* ATCC 49619 and *Streptococcus pyogenes* ATCC 12344 were obtained from Institut Pasteur (Abidjan). BD-Difco™ *Lactobacilli* of Man-Rogosa-Sharpe (MRS) broth or MRS agar, brain heart infusion agar and Columbia agar base were obtained from Fisher Scientific (France). Poloxamer 407 (P) (Lutrol® F127) of pharmaceutical grade was purchased from BASF (Germany). According to the supplier, the average molecular weight was  $11774 \text{ g}\cdot\text{mol}^{-1}$  ( $9840\text{--}14600 \text{ g}\cdot\text{mol}^{-1}$ ). Sodium alginate (A) was purchased from Roth (France), batch N° 351172083. Its weight-average molecular weight determined by size exclusion chromatography coupled to multi-angle light scattering was  $300\,000 \text{ g}\cdot\text{mol}^{-1}$ . The M:G ( $\beta$ -D-mannuronic acid: $\alpha$ -L-guluronic acid) ratio determined by  $^1\text{H}$  NMR was  $1.24 \pm 0.04$ . Bovine serum albumin and all other reagents were supplied by Sigma-Aldrich (France) and were of analytical grade. Live/dead® bacLight™ bacterial viability kit was purchased from Fisher Scientific (France). Sterile ultrapure water (resistivity 18.2 M $\Omega$ , MilliQ, Millipore, France) was used. All the antibiotic discs were from BIO-RAD (France) and the E-test from Biomérieux (France).

### 2.2. Study of *Lactobacillus crispatus*

#### 2.2.1. Growth kinetic

*L. crispatus* (1/1000 v/v) in MRS broth was incubated at 37 °C, 5% CO<sub>2</sub> to determine its stationary growth phase. Then, the number of colony-forming units was determined at the beginning ( $t_0$ ) and every three hours for 24 h, using a MRS agar plate. This test was performed in triplicate in one experiment.

#### 2.2.2. Acid production and growth at different pH

The evaluation of the acidification ability of *L. crispatus* and of the effects of low pH on its growth was achieved according to Boskey et al. (1999), with slight modifications. MRS broth was prepared and adjusted to specific initial pH (pH<sub>i</sub>) ranging from 4 to 7 with either HCl

or NaOH before autoclaving. *L. crispatus* was inoculated (1% v/v) into 10 mL of each MRS broth giving a starting concentration of about  $10^7$  cells/mL. These suspensions were incubated for 24 h at 37 °C under 5% CO<sub>2</sub>. The amount of acid produced by *L. crispatus* was indirectly determined by measuring the pH immediately after preparation ( $t_0$ ) and after a 24 h incubation ( $t_{24h}$ ) with a pH meter (Mettler Toledo equipped with an electrode Seven2GO, France). To assess the sensitivity of *L. crispatus* to the pH, the numbers of CFU/mL of each MRS broth were quantified at the beginning ( $t_0$ ) and after 24 h ( $t_{24h}$ ). This assay was performed in two separate experiments constituted of three replicates each.

### 2.2.3. Auto-aggregation and co-aggregation assays

This test was conducted to appreciate the ability of *L. crispatus* to auto-aggregate and co-aggregate *N. gonorrhoeae*. It was performed according to Verdenelli et al. (2014) with slight modifications. The cultures were harvested by centrifugation (2800 g, 10 min, 4 °C), and washed twice with sterile water (pH7). Bacterial suspensions in water of *L. crispatus* and *N. gonorrhoeae* were adjusted to 0.5 McFarland. Equal volumes (1 mL) of each suspension were mixed for 20 s using a vortex and left for 4 h at 37 °C. A droplet of the single suspensions and the mixture was then put on a glass slide immediately and after four hours. After Gram-staining, aggregates, defined as visible clumps of bacteria, were observed using a B-290 TB Optika microscope (Italy). This experiment was performed in triplicate.

### 2.2.4. Hemolytic activity

To evaluate the ability of *L. crispatus* to induce hemolysis, the hemolytic activity of *L. crispatus* was determined according to Maragkoudakis et al. (2009) with slight modifications. In short, the subculture of *L. crispatus* of 16 h in MRS broth was streaked onto Columbia agar base plates supplemented with 5% (v/v) whole sheep blood. The plates were incubated at 37 °C under 5% CO<sub>2</sub> for 24 h and 48 h in anaerobic conditions. Then, the clear zones and the color of hemolysis around the growth colonies were observed. *Streptococcus pneumoniae* ATCC 49619 and *Streptococcus pyogenes* ATCC 12344 were used as controls for respectively  $\alpha$ - and  $\beta$ -hemolysis. This experiment was performed thrice.

### 2.2.5. Antibiotic susceptibility profile

*L. crispatus* susceptibility to different classes of antibiotics was evaluated by disc (6 mm diameter) method. At least two independent sets of experiments were performed. As a control to the disc method, susceptibility to azithromycin, cefixime, ceftriaxone, ciprofloxacin, gentamicin, penicillin G and tetracycline was also evaluated by the E-test method according to the manufacturer's instructions. This method provides a convenient and quantitative test of antibiotic resistance. All the plates were incubated for 24 and 48 h. MRS agar was used in order to favor the growth of *L. crispatus*.

## 2.3. Purity control and counting of *L. crispatus*

Purity was assessed by macroscopic observation of colonies and microscopic observation after Gram staining. The serial decimal dilution method, by plating onto MRS agar medium, was used for counting total *Lactobacilli* in every suspensions and gels. Dilutions were made in PBS and after vortexing each dilution for 5 s, 100  $\mu$ L of the previous dilution were inoculated in 900  $\mu$ L of the next dilution. Then, 100  $\mu$ L of the chosen dilutions were poured on the MRS agar plates.

## 2.4. Hydrogel preparation

A concentrated mixture of polymers was prepared. Polymer solubilization was performed by using a mixer equipped with a turbine adapted to the mixing of viscous preparations (Rayneri-turbotest, Rayneri, France) under an agitation of 1000 rpm as

**Table 1**

Hydrogels containing alginate (A), poloxamer (P) with or without *L. crispatus* (L).

Acronyms	Poloxamer (% w/w)	Alginate (% w/w)	<i>L. crispatus</i> (log <sub>10</sub> CFU/5 g of gel)
P21.5A1	21.5	1	–
P21.5A1L	21.5	1	9

described by Aka-Any-Grah et al. (2010). The alginate powder (1.250 g) was gradually added under agitation at room temperature to ultrapure water (71.875 g). After complete dissolution of alginate, the poloxamer powder (26.875 g) was gradually added at 4 °C under the same agitation. After complete dissolution, this mixture was equilibrated 48 h at 4 °C to eliminate air bubbles and was autoclaved at 121 °C, 15 min before its mixing with the *Lactobacilli* suspension.

Meanwhile, frozen *L. crispatus* (–80 °C) was isolated on MRS agar for 48–72 h. Then, it was subcultured twice, first for 24 h and second for 16 h (37 °C, 5% CO<sub>2</sub>). This second subculture was centrifuged (2800 g, 10 min, 4 °C) and washed twice with sterile water before being suspended in sterile water. *L. crispatus* homogenization was achieved by vortexing. *L. crispatus* suspension was enumerated by plating serial dilutions onto MRS agar.

Final gels with or without *L. crispatus* were obtained by mixing respectively 1 mL of sterile water or 1 mL of the *L. crispatus* suspension to 4 g of the concentrated polymer mixture. This allowed obtaining two types of gels (P21.5A1 and P21.5A1L) whose final compositions are presented in Table 1. P21.5A1L contained 9 log<sub>10</sub> CFU of *L. crispatus* per gel sample (5 g).

## 2.5. Preparation of hydrogels diluted by simulated vaginal fluid

Previous studies showed that 5 mL of gels were able to properly cover the human vaginal epithelium, immediately after insertion, within the first 30 min and without sexual intercourse (Barnhart et al., 2004). The volume of ambient fluid present in the vagina at any time is approximately 0.5–0.75 mL (Owen and Katz, 1999). Therefore, to mimic the maximum dilution likely to occur in the vagina after the gel administration, 5 mL of each formulation were diluted with 0.75 mL of simulated vaginal fluid (SVF). SVF containing sodium chloride, potassium hydroxide, calcium hydroxide, bovine serum albumin, lactic acid, acetic acid, glycerol, urea and glucose was prepared according to Owen and Katz (1999). It simulates the vaginal fluid from healthy, nonpregnant, premenopausal women and can be used to study vaginal formulations *in vitro*. P21.5A1 + SVF and P21.5A1L + SVF denoted respectively P21.5A1 and P21.5A1L samples diluted with SVF. The aim of this test was to assess the influence of the dilution by SVF on the thermogelling and the rheological properties of the formulations.

## 2.6. Rheological characterization of the hydrogels

The rheological properties of the gels were assessed at 25 °C, at 37 °C and after dilution of the gels by SVF at 37 °C. Experiments were conducted on a rotational rheometer ARG2 (TA instruments, New Castle, USA) equipped with an aluminum cone/plate geometry (diameter 40 mm, angle 1° and cone truncation 28  $\mu$ m) and with a solvent trap to limit evaporation during measurement. Peltier diodes, placed in the lower plate, allowed controlling the temperature. The samples were equilibrated 3 min before starting the experiments. In flow measurements, the viscosity ( $\eta$ ) was recorded as a function of the shear rate. The shear rate was increased gradually from 0.01 s<sup>-1</sup> to 1000 s<sup>-1</sup> over 3 min, maintained at 1000 s<sup>-1</sup> for 1 min and then decreased gradually from 1000 s<sup>-1</sup> to 0.01 s<sup>-1</sup> over 3 min. In oscillatory measurements, linear viscoelastic regions, where the moduli remained constant as the shear stress increased, were determined. The gelation temperature ( $T_{gel}$ ) and viscoelastic properties of the gels were

assessed under a stress value belonging to their viscoelastic linear regime. A temperature sweep from 5 to 45 °C at a rate of 1 °C/min was performed at a frequency of 1 Hz, and the elastic modulus ( $G'$ ) as well as the viscous modulus ( $G''$ ) were recorded as a function of the temperature. The gelation temperature ( $T_{gel}$ ) was determined as the temperature of the crossover of  $G'$  and  $G''$ .  $G'$  and  $G''$  were also recorded during frequency sweeps from 0.01 to 50 Hz. These experiments were performed in triplicate.

### 2.7. pH measurement of the gels

pH of the gels was measured at room temperature with a pH-meter Mettler Toledo Seven2Go, suited for measurements in viscous aqueous media. This experiment was performed in triplicate.

### 2.8. Assessment of the distribution of *L. crispatus* within the gel

The distribution and viability of *L. crispatus* within the gels were assessed by using Syto9 that stained both living and dead bacteria in green and propidium iodide that stained only dead bacteria in red. When used simultaneously, Syto9 seemed to allow the observation of living bacteria in green, and propidium iodide the observation in red of the dead ones (Moore et al., 2015). These fluorescent stains were introduced at 1/1000 (v/w) in the gels. In short, they were introduced in the 1-mL *L. crispatus* suspension before mixing it with the gels in the liquid state. Then, they were immediately observed by microscope. This study was performed with an inverted confocal laser scanning microscope LSM 510-Meta (Carl Zeiss, Germany) using a Plan-Apochromat 63X/1.4 objective lens, equipped with an argon (488 nm excitation wavelength) and a helium neon laser (543 nm excitation wavelength). The green and the red fluorescence emissions were collected with a 505–550 nm band-pass and a 560 nm long pass emission filter respectively, under a sequential mode. The pinhole was set at 1.0 Airy unit. For each condition, single 2D images were collected as well as 3D images with an image every 0.9  $\mu\text{m}$  along the z axis to reach a thickness of 32  $\mu\text{m}$  taken arbitrarily. 12 bit numerical images were acquired with LSM 510 software version 3.2.

### 2.9. Stability studies of the gel P21.5A1L

P21.5A1L was stored over six months at 4 and 25 °C, respectively below and above the gelation temperature, in order to assess its stability. The gel viscosity at a shear rate of 125  $\text{s}^{-1}$  and pH were measured as previously described. Counting on MRS agar plate was performed to investigate the culturability of cells. In brief, after serial decimal dilutions, three dilutions were plated on MRS agar. Plates were incubated at 37 °C for 48 h before counting the colony forming units. Otherwise, *L. crispatus* distribution and viability were evaluated by confocal laser scanning microscopy. Briefly, the fluorescent stains (Syto9 and propidium iodide) were introduced at 1/1000 (v/w) in the liquid gels containing *L. crispatus*, vortexed and immediately observed by confocal microscopy as previously described in Section 2.8.

### 2.10. Inhibition of the growth of *N. gonorrhoeae*

For the preparation of *N. gonorrhoeae* suspension, the frozen stock was isolated on Thayer-Martin medium plate and incubated for 18 h at 37 °C in a moist atmosphere enriched with 5%  $\text{CO}_2$ . These conditions were used because autolysis may occur during prolonged incubation, and it may be difficult to obtain a suspension from growth on agar plates. Then, colonies were suspended in NaCl 0.85% to a turbidity equivalent to 0.5 McFarland standard. These suspensions contained  $10^6$  *N. gonorrhoeae* cells/mL. They were mixed thoroughly using a vortex mixer to break up clumps of growth.

The inhibition of *N. gonorrhoeae* was evaluated by using a modified version of the agar overlay technique of Amant et al. (2002). Fig. 1




Fig. 1. Schematic depiction of the inhibition of *N. gonorrhoeae* test: ① brain heart infusion agar at pH 5 or 6.5, ② spots of gels or suspensions containing *L. crispatus* after incubation 24 h, 37 °C, ③ chocolate agar medium, ④ spreading of *N. gonorrhoeae*, ⑤ inhibition zones.

presents the method schematically. Brain heart infusion agars (BHIA) with pH adjusted either to 5 or 6.5 were prepared before being autoclaved at 121 °C over 15 min. Gels or suspensions containing *L. crispatus* were inoculated onto BHIA plates (60 mm diameter), using respectively a sterile handle or a micropipette to obtain spots of 0.5 g for the gels or of 50  $\mu\text{L}$  for the suspensions. After 24 h of incubation, 4 mL of chocolate agar (containing proteose peptone, dextrose, sodium chloride, disodium phosphate, agar, hemoglobin) were poured onto the BHIA plates and allowed to solidify. Then, 500  $\mu\text{L}$  of *N. gonorrhoeae* suspension were spread onto the agar overlay and incubated for 24 h. The presence of a zone of growth inhibition was considered as positive for inhibition. Control experiments were performed by using the same protocol without the step of spot formation. Moreover, the effect of a gel without *L. crispatus* was also assessed. For all experiments, the number of *L. crispatus* in the suspensions or the gels was confirmed by standard serial dilution and culture. The thickness of each agar layer was about 2 mm.

## 3. Results and discussion

In this study, a well identified and characterized reference strain that originated from a human vagina and that had already shown its efficacy on *N. gonorrhoeae* (Amant et al., 2002; Breshears et al., 2015) was selected. Its probiotic benefits such as its acidification ability and its capacity to auto-aggregate or co-aggregate *N. gonorrhoeae* were first confirmed before formulation development and *in vitro* efficacy studies.

### 3.1. Characterization of *L. crispatus*

Based on published data, *L. crispatus* suspensions containing  $9 \log_{10}$  CFU/mL were selected. Amant et al. (2002) showed the effectiveness of different dilutions of  $10^8$  *L. crispatus* on *N. gonorrhoeae* and Reid et al. (2001) showed the effectiveness of over  $10^8$  viable probiotic per day to restore and maintain a normal vaginal flora. An expert consensus document stated that the minimal number of viable cells should be  $1 \times 10^9$  CFU administered per day (Hill et al., 2014).

*L. crispatus* growth kinetic test allowed determining its stationary phase that began after 9 h of culture. Based on this result, for all the tests, cultures of 16 h of incubation were used to ensure reproducible physiological and metabolic states of the strain.

As regards *L. crispatus* acidification ability, this strain was grown in either standard growth medium (pH<sub>i</sub> 6.5) or in modified pH growth medium (4, 5, 6, 7). The use of these pH values was based on the fact

**Table 2**

Growth of *L. crispatus* and reduction in pH values due to *L. crispatus* acid production obtained with different initial pH values. Mean of three replicates on two separate experiments.

Initial pH	4.00 ± 0.01	5.00 ± 0.01	6.00 ± 0.01	6.50 ± 0.01	7.00 ± 0.01
Increase in the number of <i>L. crispatus</i> at 24 h, 37 °C, 5% CO <sub>2</sub> (Log <sub>10</sub> CFU/mL)	1.19 ± 0.23	1.57 ± 0.41	1.85 ± 0.46	1.88 ± 0.11	2.00 ± 0.16
Reduction in pH due to <i>L. crispatus</i> at 24 h, 37 °C, 5% CO <sub>2</sub>	0.74 ± 0.17	1.49 ± 0.13	1.96 ± 0.02	2.24 ± 0.08	2.39 ± 0.04


that vaginal pH varies between 3.5 and 5.5 and increases up to 7 in the presence of seminal fluid (O'Hanlon et al., 2013; Owen and Katz, 1999). Therefore, the growth and the acid production of *L. crispatus* were simultaneously evaluated in MRS at pH ranging from 4 to 7 to mimic this vaginal pH. In MRS, the *Lactobacilli* had the nutrients they needed to grow and pH was the only modified parameter in order to assess its influence. The growth of *L. crispatus* was favored at pH ranging from 6 to 7 (Table 2). This pH range corresponded to the pH of the mixture of polymers, which should thus be favorable for *L. crispatus* addition. Otherwise, whatever the pH<sub>i</sub> of MRS, a decrease in pH values was observed after 24 h of incubation at 37 °C and 5% CO<sub>2</sub>, mimicking the vaginal conditions. The variations of pH are given in Table 2. They were also higher at pH varying between 6 and 7, suggesting a correlation between *L. crispatus* viability and acid production. A reduction of pH by *L. crispatus* indicated indirectly an acidification due to lactic acid production. Thus, this result suggested higher lactic acid production at pH higher than 6. Both pH and lactic acid concentration of a media may inactivate pathogens individually or in combination. O'Hanlon et al. (2013) showed that as the alkaline pH of the vagina due to seminal fluid reduced the protective action of vaginal acidity against pathogens, the level of vaginal lactic acid was likely to reduce the transmission of vaginal acid-sensitive pathogens. As only protonated lactic acid might have microbicidal activity, it would be better to have a pH below the pKa of lactic acid (3.90) (Tachedjian et al., 2017). In this study, the quantity of protonated lactic acid was not measured, but as the final pH in each sample was between 3.1 and 3.9, it can be supposed that lactic acid was in its protonated state favorable for its antibacterial activity. The final pH in each sample was comparable to the pH of healthy vagina dominated by *Lactobacilli* as described by O'Hanlon et al. (2013).

Moreover, Graver and Wade (2011) showed the important role of acidification in the inhibition of *N. gonorrhoeae*. For Foschi et al. (2017), the presence of lactate seemed to be crucial for the anti-gonococcal activity, especially for pH values ranging from 4.4 to 5.3, indicating that the presence of hydrogen ions was necessary but not sufficient to inhibit gonococci. In our study, results of the acid production and the growth of *L. crispatus* in the pH range of 4 to 7 predicted a favorable growth in the vagina containing natural nutrients and favorable

conditions for the inhibition of *N. gonorrhoeae* (see Section 3.5). Amant et al. (2002) also showed the ability of this *Lactobacillus* strain to inhibit *N. gonorrhoeae* both at acid and neutral pH. Based on these studies, the higher reduction in pH related to higher lactic acid production was considered as more interesting.

The auto-aggregation and co-aggregation with *N. gonorrhoeae* properties of *L. crispatus* were investigated. Fig. 2 shows their organization in suspension after a 4 h-incubation time in suspension. *L. crispatus* formed large and dense visible clumps (Fig. 2A) whereas *N. gonorrhoeae* formed a clump similar to that observed by Anderson et al. (2016) (Fig. 2C), with an aspect different than that of *L. crispatus* (Fig. 2A). Small and widely distributed aggregates were observed in the mixtures of *L. crispatus* and *N. gonorrhoeae* (Fig. 2B). They were arranged as microcolonies similar to the ones observed by Foschi et al. (2017). *L. crispatus* can change its organization in the presence of pathogens to co-aggregate with them. Reid et al. (1990) showed that when *Lactobacilli* formed co-aggregates and bound to pathogens, this resulted in returns to homeostasis, because co-aggregation created a hostile biochemical micro-environment around the pathogen and prevented it from continuation of growth and domination of the niche.

Regarding the security aspect associated with the use of this *L. crispatus* strain, two parameters were studied, its hemolytic activity and its antimicrobial resistance. Hemolytic activity test showed that the Columbia sheep blood agar aspect around the colonies was unchanged, meaning *L. crispatus* did not exhibit hemolysis. It is a non-hemolytic bacterium. This result was in accordance with many reports (Ambalam et al., 2012; Kassaa et al., 2014; Maragkoudakis et al., 2006). The antibiotic resistance is another key factor for probiotics as the level of susceptibility to the antimicrobial agents is species-dependent. Table 3 presents the results of the disc method. The E-test and the disc method gave similar results for the antibiotics studied by both methods. The resistance to gentamicin and ciprofloxacin was observed both by E-test and disc diffusion methods. Results showed that *L. crispatus* was resistant to an aminoglycoside (gentamicin), quinolones (ciprofloxacin, nalidixic acid, pefloxacin) and a lincosamide (clindamycin) (Table 3). Several studies have reported intrinsic resistance of *Lactobacilli* to quinolones, gentamicin, and other antibiotics (Danielsen and Wind, 2003;



**Fig. 2.** Aspects of clumps in aggregation tests after 4 h of incubation (×100). A: *L. crispatus*; B: mixture of *L. crispatus* and *N. gonorrhoeae*; C: *N. gonorrhoeae*. Scale bars correspond to 10 μm.

Štšepetova et al., 2017; Temmerman et al., 2003). According to the European Food Safety Authority (EFSA) guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance, bacterial strains carrying intrinsic resistance present a minimal risk for horizontal spread and thus, may be used as a food additive. Based on these *in vitro* tests, *L. crispatus* is an interesting probiotic candidate. However, further studies should be performed to search for pathogenicity genes, as well as *in vivo* studies to confirm that this *L. crispatus* strain would not induce any pathogenicity and could be regarded as a safe microorganism for a vaginal administration.

### 3.2. Preparation and rheological characterization of gels

In a second step of our study, *L. crispatus* was incorporated in an aqueous mixture of poloxamer 407 and sodium alginate in order to develop a formulation with characteristics that were suitable for a vaginal administration. In a preliminary optimization step, the concentration of poloxamer 407 (21.5%) and sodium alginate (1%) were selected in order to obtain a formulation that remained in gel state at 37 °C, even after dilution with SVF, with minimal polymer concentrations. Thereafter, the study focused on this gel denoted P21.5A1 and on its corresponding gel (P21.5A1L) containing *L. crispatus* at 9 log<sub>10</sub> CFU per gel sample (5 g). The counting of *Lactobacilli* in both suspensions and gels after their preparation showed that, in the gel, it represented 1/5 of the number in the suspension. That corresponded to the dilution

ratio of *L. crispatus* suspension (1 mL) with the gel (4 g). This result suggested that the fabrication process was not deleterious for the *Lactobacilli*.

Both gels were characterized by rheology (Fig. 3, Table 4). The gel without *L. crispatus*, P21.5A1, showed a shear-thinning behavior (Fig. 3A, B). This behavior should allow an easy administration. This formulation was also non-thixotropic even after dilution by the simulated vaginal fluid (Fig. 3A, B). Therefore, as soon as the shear was removed, the viscosity returned to its initial high value, which should be favorable to maintain the gel at the administration site and to increase the residence time of the formulation in the vagina. P21.5A1 also had a thermogelling behavior (Fig. 3C). Below T<sub>gel</sub>, the elastic modulus (G') was lower than the viscous modulus (G'') revealing a dominant viscous behavior. Above T<sub>gel</sub>, G' was higher than G'' showing a dominant elastic behavior. P21.5A1 gelation temperature was 19 ± 1 °C. After dilution with SVF, T<sub>gel</sub> was increased (Fig. 3C, D, Table 4) whereas the viscoelastic moduli values decreased due to the diminution of the concentration of poloxamer (Fig. 3C versus D and E versus F, Table 4). Aka-Any-Grah et al. (2010) also observed this phenomenon. Interestingly, when *L. crispatus* was introduced into the gel (P21.5A1L), the rheological properties were similar to those of P21.5A1 (Fig. 3, Table 4). Thus, *L. crispatus* did not significantly affect the rheological properties of this mixture of poloxamer 407 and sodium alginate, even after dilution with SVF.

**Table 3**

Antibiotics susceptibility of *L. crispatus* by disc diffusion method as a mean of at least two repetitions, showing highlighted in gray the antibiotics to which *L. crispatus* was resistant.

Antibiotic discs (dose/disc)	Inhibition zone diameter (mm)	Antibiotic discs (dose/disc)	Inhibition zone diameter (mm)
<b>PENICILLIN CLASS</b>		<b>TETRACYCLINES CLASS</b>	
Penicillin G (10µg)	26	Doxycycline (DOX, 30 µg)	26
Ampicillin (AMP, 10 µg)	25	Minocycline (MN, 30 µg)	29
Amoxicillin (AMX, 25 µg)	24	Tetracycline (TET, 30 µg)	28
Oxacillin (OXA, 1 µg)	27	<b>MACROLIDES CLASS</b>	
Piperacillin (PIP, 75 µg)	34	Azithromycin (AZM, 15 µg)	20
Ticarcillin (TIC, 75 µg)	37	Spiramycin (SPN, 100 µg)	18
Amoxicillin-clavulanic acid (AMC, 20/10 µg)	27	Erythromycin (ERY, 15 µg)	30
Piperacillin-tazobactam (PPT, 75/10 µg)	24	<b>CHLORAMPHENICOL CLASS</b>	
Ticarcillin-clavulanic (TCC, 75/10 µg)	36	Chloramphenicol (CHL, 30 µg)	29
<b>CEPHALOSPORIN CLASS</b>		<b>LINCOSAMIDES CLASS</b>	
Cephalexin (CEF, 30 µg)	30	Lincomycin LCN, 15 µg)	13
Cefuroxime (CXM, 30 µg)	24	Clindamycin (CMN, 2 µg)	6
Cefixime (CFM, 10 µg)	28	<b>QUINOLONES CLASS</b>	
Ceftazidime (CAZ, 30 µg)	21	Pefloxacin (PEF, 5 µg)	0
Cefpodoxime (CPD, 10 µg)	19	Ciprofloxacin (CIP, 5 µg)	0
Ceftriaxone (CFO, 30 µg)	31	Nalidixic acid (NAL, 30 µg)	0
<b>AMINOGLYCOSIDES CLASS</b>		<b>ANSAMYCIN CLASS</b>	
Gentamicin (GMI, 15µg)	0	Rifampycin (RAM, 30 µg)	27
<b>CARBAPENEM CLASS</b>		<b>GLYCOPEPTIDES CLASS</b>	
Imipenem (IPM, 10 µg)	25	Vancomycin (VAN, 30 µg),	19
		Teicoplanin (TEC, 30 µg)	15




Fig. 3. Comparison of the rheological properties of P21.5A1 and P21.5A1L: flow properties (A, B), temperature sweep displaying one data point out of ten (C, D), and viscoelastic properties at 1 Hz (E, F), for gels without SVF (A, C, E) and with SVF (B, D, F). For P21.5A1: (■)  $\eta$ , (■)  $G'$ , (□)  $G''$ , and for P21.5A1L: (◆)  $\eta$ , (◆)  $G'$ , (◇)  $G''$ . Note that P21.5A1 and P21.5A1L curves are superimposed.

### 3.3. Distribution of *L. crispatus* within the gel


For further characterization of the gel containing *L. crispatus*, the distribution of *L. crispatus* immediately after the gel preparation was

studied by confocal fluorescence microscopy (CLSM), using both Syto9 and propidium iodide (Fig. 4). Zotta et al. (2012) showed the usefulness of two stain indicators for optimal results in the evaluation of cells viability. In the present study, Syto9 was used to stain live bacteria in

**Table 4**

Influence of *L. crispatus* on the rheological properties of the gel containing poloxamer 407 at 21.5% and sodium alginate at 1% at three different conditions: 25 °C, 37 °C and 37 °C after dilution with SVF.

Samples	T <sub>gel</sub> (°C)	Viscoelastic properties at 1 Hz			Flow properties
		Conditions	G' (10 <sup>3</sup> Pa)	G'' (10 <sup>3</sup> Pa)	
P21.5A1	19 ± 1	25 °C	13.5 ± 0.4	1.0 ± 0.2	Shear-thinning Non-thixotropic
		37 °C	17.6 ± 0.5	0.5 ± 0.6	
P21.5A1 + SVF	24 ± 1	37 °C + SVF	10.5 ± 0.2	0.7 ± 0.2	
P21.5A1L	19 ± 1	25 °C	13.9 ± 0.3	1.1 ± 0.5	
		37 °C	16.5 ± 0.4	0.7 ± 0.1	
P21.5A1L + SVF	23 ± 1	37 °C + SVF	10.1 ± 0.3	0.7 ± 0.2	




**Fig. 4.** Representative confocal microscopy image of the distribution of *L. crispatus* within the P21.5A1L hydrogel immediately after their preparation, showing a large majority of *L. crispatus* in green (living bacteria). Dead bacteria appear in red. Images correspond to the stacking of 37 images collected along the z-axis. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

green whereas propidium iodide was used to stain dead cells. Almost all the *L. crispatus* cells were green stained confirming their viability after their introduction into the gel. The distribution seemed to be similar at all the observed points, from two different wells of the same gel. Thus, CLSM showed a homogeneous distribution of *L. crispatus* in the gel along the x, y and z axes (Fig. 4). This distribution of *L. crispatus* was repeatable and reproducible, showing the reproducibility of the method of gel preparation. This homogeneous distribution of *L. crispatus* in the gel should be favorable to a homogeneous distribution of *L. crispatus* in the vagina after administration.

#### 3.4. Influence of the storage conditions

The stability of the gel P21.5A1L was examined for 6 months at two different storage conditions: 4 and 25 °C. Viscosity of the gel (Fig. 5A, B) as well as its pH (Fig. 5C, D) remained unchanged over these 6 months of storage at both temperatures (Fig. 5A, C and Fig. 5B, D). However, the viability and the culturability of formulated *L. crispatus* were modified (Figs. 6 and 7). The number of *L. crispatus* assessed by counting on MRS agar plate decreased drastically after 14 days of storage at 4 °C (Fig. 6) and after 2 days at 25 °C (Fig. 7). The number of *L. crispatus* was assessed by confocal microscopy using Syto9 and propidium iodide (Fig. 6). Samples were analysed by two types of acquisition, the z-stack acquisition of two different areas and the single stack of



**Fig. 5.** Viscosity (A, B) and pH (C, D) measurements of a gel containing poloxamer 407 at 21.5%, sodium alginate at 1% and *L. crispatus* at 9 log<sub>10</sub> CFU per gel unit (5 g), during its storage over six months at 4 °C (A, C) or 25 °C (B, D).




Fig. 6. Viability of *L. crispatus* contained in the gel P21.5A1L after storage at 4 °C. Confocal laser scanning microscopy observations were made immediately after preparation (D0) and at days 1, 2, 14, 180 (D1-D180). Counts on MRS agar plate expressed in  $\log_{10}$  CFU/g. Examples of projection of all bacteria, of green-stained bacteria (living) and of red-stained bacteria (dead). Scale bar corresponds to 50  $\mu$ m. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)




Fig. 7. Viability of *L. crispatus* contained in the gel P21.5A11 after storage at 25 °C. Confocal laser scanning microscopy observations were made immediately after preparation (D0) and at days 1, 2, 14, 180 (D1-D180). Counts on MRS agar plate expressed in  $\log_{10}$  CFU/g. Examples of projection of all bacteria, of green-stained bacteria (living) and of red-stained (dead) bacteria. Scale bar corresponds to 50  $\mu$ m. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

eight different areas. The coefficient of correlation between the two types of image acquisition was 0.93. Despite the observation of green-labeled bacteria on the images of the confocal microscopy, there was no bacterial count by agar count method on MRS plate at D180 (storage at 4 °C) and at D14 and D180 (storage at 25 °C). This result suggested the development of viable but nonculturable (VNC) bacteria in the gel during storage at both 4 °C and 25 °C. This can be due to the absence of nutrient inducing a stress of *L. crispatus* in the gel. Indeed, the enumeration by agar plate method often leads to an underestimation of bacterial total number due to the formation of cells chains and clumps or to the induction of VNC state after an exposure to stress or starvation (Léonard et al., 2015; Rault et al., 2007; Zotta et al., 2009). These results are in accordance with several studies which showed that cell viability estimated by microscopy was higher than viability assessed by plate counts. VNC cells can not be cultured using standard microbiological media because they are incapable of undergoing the sustained cellular division required to form a colony on regular agar media but they often maintain a potential for metabolic activity at the single cell level (Zotta et al., 2009).

As the number of viable *L. crispatus* decreased in gel during storage, further studies are needed to preserve its viability over time. In this respect, hydrogel lyophilization, addition of prebiotics in the formulation, or extemporaneous mixing of gel and *L. crispatus* might be interesting strategies.

### 3.5. Efficacy of inhibition of *N. gonorrhoeae*

The ability of *L. crispatus* to inhibit the growth of *N. gonorrhoeae* *in vitro*, was assessed at two different pH (5, 6.5) (Table 5). In the absence of *L. crispatus*, *N. gonorrhoeae* grew onto chocolate agar at pH 6.5 but did

not grow onto this media at pH 5.0. The inhibition of *N. gonorrhoeae* was due to the acidic environment. After deposition of spots of *L. crispatus* suspension onto BHIA at pH 6.5, an inhibition zone of *N. gonorrhoeae* was clearly observed. These results were in accordance with those of Foschi et al. (2017), who demonstrated that the *L. crispatus* strains they studied were also able to counteract *N. gonorrhoeae* viability through multiple mechanisms (acidic environment creation, lactate production, biosurfactant production and co-aggregation), and could represent a new potential probiotic strategy for the prevention of gonorrhea in women.

The gel P21.5A1 alone had no effect on *N. gonorrhoeae* growth. Conversely, at pH 6.5, the P21.5A1L gel containing *L. crispatus* inhibited the growth of pathogens (Table 5) with an efficacy depending on *L. crispatus* load. *L. crispatus* was thus responsible of the inhibition by the gel at pH 6.5. When using BHIA pH 6.5, the inhibition zone of the suspension containing 8 log<sub>10</sub> *L. crispatus* was similar to the inhibition zone of the gel containing 9 log<sub>10</sub> *L. crispatus*. The gel, due to its viscosity, could slow down the diffusion of substances that are produced by *L. crispatus* and are involved in the inhibition mechanisms. Despite this lower *in vitro* efficacy compared to a simple *L. crispatus* suspension, gels remain interesting formulations. Indeed, liquid suspensions are known to lead to a rapid flow and clearance after vaginal administration whereas the gel will have a higher residence time due to its viscosity and mucoadhesive properties. Otherwise, the method used to assess the inhibition of *N. gonorrhoeae* only explored the influence of the pH and the diffusion of inhibitory molecules through the agar layer (~2 mm). Further studies by direct contact with *N. gonorrhoeae* should be performed to determine if *L. crispatus*, when incorporated in gel formulations, preserves all its inhibition properties on *N. gonorrhoeae* under the conditions prevailing in the vaginal cavity *in vivo*.

**Table 5**

Inhibition of the growth of *N. gonorrhoeae* *in vitro* by agar overlaid method, after 24 h of incubation at 37 °C, 5% CO<sub>2</sub>. Comparative study of *L. crispatus* suspension and of gels P21.5A1 and P21.5A1L. Four different experiments (tests).

		Test 1	Test 2	Test 3	Test 4
Control : Effect of BHIA pH	Position ② of Figure 1	No spot	No spot	No spot	No spot
	Inhibition diameter, BHIA at pH 5	≥ 60 mm	≥ 60 mm	≥ 60 mm	≥ 60 mm
	Inhibition diameter, BHIA at pH 6.5	No inhibition	No inhibition	No inhibition	No inhibition
<i>L. crispatus</i> suspension	Position ② of Figure 1	Spot	Spot	Spot	Spot
	<i>L. crispatus</i> counting (log <sub>10</sub> CFU/spot)	8.52	8.33	8.12	8.35
	Inhibition diameter, BHIA at pH 5	≥ 60 mm	≥ 60 mm	≥ 60 mm	≥ 60 mm
	Inhibition diameter, BHIA at pH 6.5	30 mm	28 mm	30 mm	31 mm
Control : Effect of gel P21.5A1	Position ② of Figure 1	Spot	Spot	Spot	Spot
	<i>L. crispatus</i> counting (log <sub>10</sub> CFU/spot)	No <i>L. c.</i> *			
	Inhibition diameter, BHIA at pH 5	≥ 60 mm	≥ 60 mm	≥ 60 mm	≥ 60 mm
	Inhibition diameter, BHIA at pH 6.5	No inhibition	No inhibition	No inhibition	No inhibition
P21.5A1L	Position ② of Figure 1	Spot	Spot	Spot	Spot
	<i>L. crispatus</i> counting (log <sub>10</sub> CFU/spot)	7.32	7.72	9.32	9.10
	Inhibition diameter, BHIA at pH 5	≥ 60 mm	≥ 60 mm	≥ 60 mm	≥ 60 mm
	Inhibition diameter, BHIA at pH 6.5	15 mm	12 mm	31 mm	30 mm

\* *L. c.*: *L. crispatus*.

#### 4. Conclusion

This study showed the probiotic potential of *L. crispatus* ATCC 33197 and its ability to inhibit *N. gonorrhoeae*. *L. crispatus* can be considered as a good candidate to be used in the development of vaginal formulations for the prevention of gonorrhoea. Gels containing poloxamer 407 at 21.5% and alginate at 1% with or without *L. crispatus* ATCC 33197 showed rheological properties favorable for a vaginal administration. Their process of preparation was not deleterious for the *Lactobacilli* cells. *L. crispatus* was able to inhibit *N. gonorrhoeae* even when incorporated in the gel. Therefore, this vaginal gel could be promising as a single-dose system intended to be administered to women at risk due to a history of vaginal infections and to women having naturally a deficiency of *lactobacilli* in their vaginal flora. Such treatment might limit gonorrhoea transmission in women that do not have the possibility to negotiate the use of condom during sexual intercourses. Yet, *L. crispatus* viability should be optimized by lyophilization or the addition of some nutrients in the formulation and *in vivo* studies should also be conducted to evaluate the efficacy and the safety of the gel. The number, frequency and timing of administration, as well as the effect of sexual intercourses, are important parameters to assess in further clinical studies.

#### CRedit authorship contribution statement

**K.C. N'Guessan Gnaman:** Conceptualization, Methodology, Investigation, Visualization, Writing - original draft. **S. Bouttier:** Conceptualization, Methodology, Investigation, Writing - review & editing. **A. Yeo:** Conceptualization, Methodology, Writing - review & editing. **A.A.S. Aka Any-Grah:** Conceptualization, Supervision, Writing - review & editing. **S. Geiger:** Conceptualization, Supervision, Writing - review & editing. **N. Huang:** Methodology, Writing - review & editing. **V. Nicolas:** Methodology, Writing - review & editing. **S. Villebrun:** Investigation. **H. Faye-Kette:** Conceptualization, Writing - review & editing. **G. Ponchel:** Conceptualization, Writing - review & editing. **A.A. Koffi:** Conceptualization, Supervision, Writing - review & editing, Funding acquisition, Project administration. **F. Agnely:** Conceptualization, Supervision, Writing - review & editing, Funding acquisition, Project administration.

#### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

#### Acknowledgements

This work was supported by Institut de recherche et de développement (IRD), Franco-Ivorian cooperation, Campus France, AMRUGE-CI/C2D grant (support to the modernization and reform of universities and colleges of Côte d'Ivoire). The authors thank the region Île-de-France for the purchase of the confocal microscope and are grateful to Luc Picton and Christophe Rihouey from Laboratoire Polymères, Biopolymères, Surfaces, UMR 6270 CNRS, Université de Rouen, for the determination of alginate molecular weight and Charles Konan Kouassi from Université Abobo-Adjamé for his technical help during optical microscopy observations. Clémence N'Guessan acknowledges Université Paris-Saclay for her international dual degree PhD grant.

#### References

Aka-Any-Grah, A., Bouchemal, K., Koffi, A., Agnely, F., Zhang, M., Djabourov, M., Ponchel, G., 2010. Formulation of mucoadhesive vaginal hydrogels insensitive to dilution with vaginal fluids. *Eur. J. Pharm. Biopharm.* 76, 296–303.

- Amant, D.C.S., Valentin-Bon, I.E., Jerse, A.E., 2002. Inhibition of *Neisseria gonorrhoeae* by *Lactobacillus* species that are commonly isolated from the female genital tract. *Infect. Immun.* 70, 7169–7171.
- Ambalam, P., Ramoliya, J.M., Dave, J.M., Vyas, B.R.M., 2012. Safety assessment of potential probiotic strains *Lactobacillus rhamnosus* 231 and *Lactobacillus rhamnosus* v92 in mouse model. *Int. J. Bioassays* 2, 333–337.
- Anderson, M.T., Byerly, L., Apicella, M.A., Seifert, H.S., 2016. Seminal plasma promotes *Neisseria gonorrhoeae* aggregation and biofilm formation. *J. Bacteriol.* 198, 2228–2235.
- Antonio, M.A.D., Hillier, S.L., 2003. DNA fingerprinting of *Lactobacillus crispatus* strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. *J. Clin. Microbiol.* 41, 1881–1887.
- Antonio, M.A.D., Hawes, S.E., Hillier, S.L., 1999. The identification of vaginal *Lactobacillus* species and the demographic and microbiologic characteristics of women colonized by these species. *J. Infect. Dis.* 180, 1950–1956.
- Barnhart, K.T., Pretorius, E.S., Timbers, K., Shera, D., Shabbout, M., Malamud, D., 2004. *In vivo* distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. *Contraception* 70, 498–505.
- Boskey, E.R., Telsch, K.M., Whaley, K.J., Moench, T.R., Cone, R.A., 1999. Acid production by vaginal flora *in vitro* is consistent with the rate and extent of vaginal acidification. *Infect. Immun.* 67, 5170–5175.
- Breshers, L.M., Edwards, V.L., Ravel, J., Peterson, M.L., 2015. *Lactobacillus crispatus* inhibits growth of *Gardnerella vaginalis* and *Neisseria gonorrhoeae* on a porcine vaginal mucosa model. *BMC Microbiol.* 15.
- Bruce, A.W., Reid, G., 1988. Intravaginal instillation of *Lactobacilli* for prevention of recurrent urinary tract infections. *Can. J. Microbiol.* 34, 339–343.
- Caramella, C.M., Rossi, S., Ferrari, F., Bonferoni, M.C., Sandri, G., 2015. Mucoadhesive and thermogelling systems for vaginal drug delivery. *Adv. Drug Deliv. Rev.* 92, 38–52.
- Chaluvadi, S., Hotchkiss Jr., A.T., Call, J.E., Luchansky, J.B., Phillips, J.G., Liu, L., Yam, K.L., 2012. Protection of probiotic bacteria in a synbiotic matrix following aerobic storage at 4 °C. *Benef. Microbes* 3, 175–187.
- Cohen, M.S., 2004. HIV and sexually transmitted diseases: lethal synergy. *Top. HIV Med. Publ. Int. AIDS Soc. U.S.A.* 12, 104–107.
- Cook, M.T., Brown, M.B., 2018. Polymeric gels for intravaginal drug delivery. *J. Control. Release* 270, 145–157.
- Czaja, C.A., Stapleton, A.E., Yarova-Yarovaya, Y., Stamm, W.E., 2007. Phase I trial of a *Lactobacillus crispatus* vaginal suppository for prevention of recurrent urinary tract infection in women. *Infect. Dis. Obstet. Gynecol.* 2007, 35387. <https://doi.org/10.1155/2007/35387>.
- Danielsen, M., Wind, A., 2003. Susceptibility of *Lactobacillus spp.* to antimicrobial agents. *Int. J. Food Microbiol.* 82, 1–11.
- Dumortier, G., Grossiord, J.L., Agnely, F., Chaumeil, J.C., 2006. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. *Pharm. Res.* 23, 2709–2728.
- Foschi, C., Salvo, M., Cevenini, R., Parolin, C., Vitali, B., Marangoni, A., 2017. Vaginal *Lactobacillus* reduce *Neisseria gonorrhoeae* viability through multiple strategies: an *in vitro* study. *Front. Cell. Infect. Microbiol.* 7.
- Giuliano, E., Paolino, D., Fresta, M., Cosco, D., 2018. Mucosal applications of Poloxamer 407-based hydrogels: an overview. *Pharmaceutics* 10, 159.
- Grassi, G., Crevatin, A., Farra, R., Guarneri, G., Pascotto, A., Rehmers, B., Lapasin, R., Grassi, M., 2006. Rheological properties of aqueous Pluronic-alginate systems containing liposomes. *J. Colloid Interface Sci.* 301, 282–290.
- Graver, M.A., Wade, J.J., 2011. The role of acidification in the inhibition of *Neisseria gonorrhoeae* by vaginal *Lactobacilli* during anaerobic growth. *Ann. Clin. Microbiol. Antimicrob.* 10, 8.
- Grodstein, F., Goldman, M.B., Cramer, D.W., 1993. Relation of tubal infertility to history of sexually transmitted diseases. *Am. J. Epidemiol.* 137, 577–584.
- Hemmerling, A., Harrison, W., Schroeder, A., Park, J., Korn, A., Shiboski, S., Foster-Rosales, A., Cohen, C.R., 2010. Phase 2a study assessing colonization efficiency, safety, and acceptability of *Lactobacillus crispatus* CTV-05 in women with bacterial vaginosis. *Sex. Transm. Dis.* 37, 745–750.
- Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., et al., 2014. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nat. Rev. Gastroenterol. Hepatol.* 11, 506–514.
- Huang, L., Shen, M., Li, R., Zhang, X., Sun, Y., Gao, P., Fu, H., Liu, H., He, Y., Du, Y., et al., 2016. Thermo-sensitive composite hydrogels based on poloxamer 407 and alginate and their therapeutic effect in embolization in rabbit VX2 liver tumors. *Oncotarget* 7, 73280.
- Jarvis, G.A., Chang, T.L., 2012. Modulation of HIV transmission by *Neisseria gonorrhoeae*: molecular and immunological aspects. *Curr. HIV Res.* 10, 211–217.
- Kassaa, I.A., Hamze, M., Hober, D., Chihib, N.-E., Drider, D., 2014. Identification of vaginal *Lactobacilli* with potential probiotic properties isolated from women in north Lebanon. *Microb. Ecol.* 67, 722–734.
- Laga, M., Plummer, F.A., Nzanze, H., Namaara, W., Brunham, R.C., Ndinya-Achola, J.O., Maitha, G., Ronald, A.R., D'Costa, L.J., Bhullar, V.B., 1986. Epidemiology of ophthalmia neonatorum in Kenya. *The Lancet* 2, 1145–1149.
- Lee, K.Y., Mooney, D., 2012. Alginate: properties and biomedical applications. *Prog. Polym. Sci.* 37, 106–126.
- Lefebvre, B., Martin, I., Demczuk, W., Deshaies, L., Michaud, S., Labbé, A.-C., Beaudoin, M.-C., Longtin, J., 2018. Ceftriaxone-resistant *Neisseria gonorrhoeae*, Canada, 2017. *Emerg. Infect. Dis.* 24 (2), 381–383.
- Léonard, L., Beji, O., Arnould, C., Noirot, E., Bonnotte, A., Gharsallaoui, A., Degraeve, P., Lherminier, J., Sauré, R., Oulahal, N., 2015. Preservation of viability and anti-

- Listeria activity of lactic acid bacteria, *Lactococcus lactis* and *Lactobacillus paracasei*, entrapped in gelling matrices of alginate or alginate/caseinate. *Food Control* 47, 7–19.
- Lin, H.-R., Sung, K.C., Vong, W.-J., 2004. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine. *Biomacromolecules* 5, 2358–2365.
- Liu, Y., Zhu, Y., Wei, G., Lu, W., 2009. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved *in vitro* and *in vivo* sustained-release properties. *Eur. J. Pharm. Sci.* 37, 306–312.
- Maragkoudakis, P.A., Zoumpopoulou, G., Miaris, C., Kalantzopoulos, G., Pot, B., Tsakalidou, E., 2006. Probiotic potential of *Lactobacillus* strains isolated from dairy products. *Int. Dairy J.* 16, 189–199.
- Maragkoudakis, P.A., Papadelli, M., Georgalaki, M., Panayotopoulou, E.G., Martinez-Gonzalez, B., Mentis, A.F., Petraki, K., Sgouras, D.N., Tsakalidou, E., 2009. *In vitro* and *in vivo* safety evaluation of the bacteriocin producer *Streptococcus macedonicus* ACA-DC 198. *Int. J. Food Microbiol.* 133, 141–147.
- Minnis, A.M., Padian, N.S., 2005. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. *Sex. Transm. Infect.* 81, 193–200.
- Moore, S., Kailasapathy, K., Phillips, M., Jones, M.R., 2015. Development of a viability standard curve for microencapsulated probiotic bacteria using confocal microscopy and image analysis software. *J. Microbiol. Methods* 114, 16–22.
- Nader-Macias, M.E., Juarez Tomas, M.S., 2015. Profiles and technological requirements of urogenital probiotics. *Adv. Drug Deliv. Rev.* 92, 84–104.
- O'Hanlon, D.E., Moench, T.R., Cone, R.A., 2013. Vaginal pH and microbicidal lactic acid when *Lactobacilli* dominate the microbiota. *PLoS ONE* 8, e80074.
- Owen, D.H., Katz, D.F., 1999. A vaginal fluid simulant. *Contraception* 59, 91–95.
- Palmeira-de-Oliveira, R., Palmeira-de-Oliveira, A., Martinez-de-Oliveira, J., 2015. New strategies for local treatment of vaginal infections. *Adv. Drug Deliv. Rev.* 92, 105–122.
- Pavlova, S.I., Kilic, A.O., Kilic, S.S., So, J.-S., Nader-Macias, M.E., Simoes, J.A., Tao, L., 2002. Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences. *J. Appl. Microbiol.* 92, 451–459.
- Pilcher, H., 2004. Starting to gel. *Nature* 430, 138–140.
- Querobino, S.M., de Faria, N.C., Vigato, A.A., da Silva, B.G.M., Machado, I.P., Costa, M.S., Costa, F.N., de Araujo, D.R., Alberto-Silva, C., 2019. Sodium alginate in oil-poloxamer organogels for intravaginal drug delivery: Influence on structural parameters, drug release mechanisms, cytotoxicity and *in vitro* antifungal activity. *Mater. Sci. Eng., C* 99, 1350–1361.
- Rault, A., Béal, C., Ghorbal, S., Ogier, J.-C., Bouix, M., 2007. Multiparametric flow cytometry allows rapid assessment and comparison of lactic acid bacteria viability after freezing and during frozen storage. *Cryobiology* 55, 35–43.
- Ravel, J., Gajer, P., Abdo, Z., Schneider, G.M., Koenig, S.S., Stacey, L.M., Karlebach, S., Gorle, R., Russell, J., Carol, O.T., et al., 2011. Vaginal microbiome of reproductive-age women. *PNAS* 108, 4680–4687.
- Reid, G., McGroarty, J.A., Domingue, P.A.G., Chow, A.W., Bruce, A.W., Eisen, A., Costerton, J.W., 1990. Coaggregation of urogenital bacteria *in vitro* and *in vivo*. *Curr. Microbiol.* 20, 47–52.
- Reid, G., Beuerman, D., Heinemann, C., Bruce, A.W., 2001. Probiotic *Lactobacillus* dose required to restore and maintain a normal vaginal flora. *FEMS Immunol. Med. Microbiol.* 32, 37–41.
- Reñber, S., Karavana, S.Y., Şenyiğit, Z.A., Eraç, B., Limoncu, M.H., Baloğlu, E., 2017. Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: formulation, preparation, and *in vitro/in vivo* evaluation. *Pharm. Dev. Technol.* 22, 551–561.
- Soliman, G.M., Fetih, G., Abbas, A.M., 2017. Thermosensitive bioadhesive gels for the vaginal delivery of sildenafil citrate: *in vitro* characterization and clinical evaluation in women using clomiphene citrate for induction of ovulation. *Drug Dev. Ind. Pharm.* 43 (3), 399–408.
- Stapleton, A.E., Au-Yeung, M., Hooton, T.M., Fredricks, D.N., Roberts, P.L., Czaja, C.A., Yarova-Yarovaya, Y., Fiedler, T., Cox, M., Stamm, W.E., 2011. Randomized, placebo-controlled phase 2 trial of a lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. *Clin. Infect. Dis.* 52, 1212–1217.
- Stein, Z.A., 1990. HIV prevention: the need for methods women can use. *Am. J. Public Health* 80, 460–462.
- Štšepetova, J., Taelma, H., Smidt, I., Hütt, P., Lapp, E., Aotäht, E., Mändar, R., 2017. Assessment of phenotypic and genotypic antibiotic susceptibility of vaginal *Lactobacillus* sp. *J. Appl. Microbiol.* 123, 524–534.
- Szekalska, M., Pucilowska, A., Szymańska, E., Ciosek, P., Winnicka, K., 2016. Alginate: current use and future perspectives in pharmaceutical and biomedical applications. *Int. J. Polym. Sci.* 2016. <https://doi.org/10.1155/2016/7697031>.
- Tachedjian, G., Aldunate, M., Bradshaw, C.S., Cone, R.A., 2017. The role of lactic acid production by probiotic *Lactobacillus* species in vaginal health. *Res. Microbiol.* 168, 782–792.
- Temmerman, R., Pot, B., Huys, G., Swings, J., 2003. Identification and antibiotic susceptibility of bacterial isolates from probiotic products. *Int. J. Food Microbiol.* 81, 1–10.
- Tønnesen, H.H., Karlsen, J., 2002. Alginate in drug delivery systems. *Drug Dev. Ind. Pharm.* 28, 621–630.
- Traore, Y.L., Chen, Y., Ho, E.A., 2018. Current state of microbicide development. *Clin. Pharmacol. Ther.* 104, 1074–1081.
- Vasquez, A., Jakobsson, T., Ahrne, S., Forsum, U., Molin, G., 2002. Vaginal *Lactobacillus* flora of healthy Swedish women. *J. Clin. Microbiol.* 40, 2746–2749.
- Verdenelli, M.C., Coman, M.M., Cecchini, C., Silvi, S., Orpianesi, C., Cresci, A., 2014. Evaluation of antipathogenic activity and adherence properties of human *Lactobacillus* strains for vaginal formulations. *J. Appl. Microbiol.* 116, 1297–1307.
- Verstraelen, H., Verhelst, R., Claeys, G., De Backer, E., Temmerman, M., Vaneechoutte, M., 2009. Longitudinal analysis of the vaginal microflora in pregnancy suggests that *L. crispatus* promotes the stability of the normal vaginal microflora and that *L. gasseri* and/or *L. iners* are more conducive to the occurrence of abnormal vaginal microflora. *BMC Microbiol.* 9, 116.
- Vigani, B., Faccendini, A., Rossi, S., Sandri, G., Bonferoni, M.C., Grisoli, P., Ferrari, F., 2019. Development of a mucoadhesive in situ gelling formulation for the delivery of *Lactobacillus gasseri* into vaginal cavity. *Pharmaceutics* 11, 511.
- WHO, 2016. WHO guidelines for the treatment of *Neisseria gonorrhoeae*.
- Zotta, T., Parente, E., Ricciardi, A., 2009. Viability staining and detection of metabolic activity of sourdough lactic acid bacteria under stress conditions. *World J. Microbiol. Biotechnol.*
- Zotta, T., Guidone, A., Tremonte, P., Parente, E., Ricciardi, A., 2012. A comparison of fluorescent stains for the assessment of viability and metabolic activity of lactic acid bacteria. *World J. Microbiol. Biotechnol.* 28, 919–927.